Our **Ethos** and **Sustainability Report**

2021

INARI MEDICAL®

A Message from Our CEO

We are pleased to issue our 2021 Ethos and Sustainability Report, our first written summary of our sustainability efforts and practices. Inari Medical was created 11 years ago with the goal of treating and transforming the lives of patients suffering from venous disease. As our business has expanded, so has our mission. What has not changed, however, is our Ethos. At the core of what we do is our commitment to our patients, our people, and our products. We increasingly sense responsibility, not merely opportunity, as we develop new solutions for complex disease states and unmet patient needs. We love the work, and we appreciate your continued support.

Bill Hoffman

Our Ethos

Patients first.
Always.

Take care of each other.
Constantly.

Make no small plans.
Ever.

INARI
MEDICAL®

Who We Are

We are a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our employees are dedicated to developing purpose-built systems for the treatment of significant unmet medical needs. We are steadfast in our mission to transform the lives of our patients in the most extraordinary ways.

Located in Irvine, California

We employ over **800** people

We appreciate the support of our stakeholders who have joined us in this journey.

Our Solutions

Our current product offerings consist of two minimally invasive, catheter-based mechanical thrombectomy systems which are purpose-built for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism **(VTE): deep vein thrombosis (DVT) and pulmonary embolism (PE).**

VTE is a disease caused by blood clot formation in the veins of the body and is a leading cause of death and disability worldwide. VTE represents the third most common vascular diagnosis in the United States after myocardial infarction and stroke.



PE

Most serious complication of DVT, when part of the clot travels to the lungs, causing a blockage. This is potentially life threatening.

DVT

Blood clots (aka thrombosis) that form in a deep vein, usually in the lower leg, thigh, or pelvis

FlowTriever® System



The **FlowTriever** system is a large bore catheter-based aspiration and mechanical thrombectomy system designed to remove large clots from large vessels to treat PE. **The FlowTriever** system is a single-use, sterile system that deploys over a wire and does not require capital equipment.

A **FlowTriever** system procedure is performed in a catheterization lab, interventional suite or operating room. The **FlowTriever** system is 510 (k)-cleared by the FDA for the non-surgical removal of emboli and thrombi from blood vessels, and injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. It is intended for use in the peripheral vasculature and for the treatment of PE, and is CE marked for the treatment of PE. Triever catheters, a component of the **FlowTriever** system, are also intended for use in the treatment of clot in transit from the right atrium. The system includes the FlowSaver blood return system, which is designed to enable bloodless thrombectomy for PE by filtering aspirated thrombi and blood for reinfusion back to the patient.

Based on interim results from our all-comer FLASH registry

0.2%
All-cause mortality at 48H

0.0%
Device related major adverse events

98.7% of patients were alive at **30 days.**

91% of patients experienced a decrease in the prevalence of severe dyspnea at **6 months.**

Clot removal with the ***FlowTrieve*** *system has the potential to improve the natural course of PE.*

For more details on the FLASH registry, see page 17.

While the data is compelling, we believe the **"CLOT HAUL"** images tell the real story.



We are committed to improving the treatment of patients with venous disease through continual innovation of the **FlowTriever** toolkit.

Triever24®, Triever20®, & Triever16®
Catheters

Triever20 Curve®
Catheter

FlowTriever2®
Catheter



FlowTriever®
Disks (S, M, L, XL)

FlowSaver®
Blood Return System

Large Bore Syringe



FlowStasis®
Suture Retention Device

Intri24®
Sheath

ClotTriever® System



The **ClotTriever** system is a mechanical thrombectomy system designed to core, capture and remove large clots from large vessels and is used to treat DVT. The **ClotTriever** system is a single-use, sterile system that deploys over a wire and does not require capital equipment.

A **ClotTriever** system procedure is performed in a catheterization laboratory, interventional suite or operating room.

The **ClotTriever** system is 510(k) cleared for the non-surgical removal of thrombi and emboli from blood vessels, and for the injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. It is intended for use in the peripheral vasculature including in patients with DVT, and is CE marked for the treatment of DVT.

Based on interim results from our all-comer CLOUT registry

99.6% Single-session treatment

0 mg Thrombolytics used

50 mL Median estimated blood loss

100% of patients treated with **ClotTriever** system experience medical reduction in pain at 6 months.

90% are free of moderate or severe post-thrombotic syndrome symptoms.

For more details on the CLOUT registry, see page 17.

While the data is compelling, we believe the **"CLOT HAUL"** images tell the real story.



The **ClotTriever** system is designed to treat the full range of clot chronicity, from acute to chronic.



ClotTriever
Thrombectomy System



ClotTriever
Catheter

ClotTriever BOLD™
Catheter

ClotTriever
Sheath

Our Sustainability

Since our inception, **our Ethos** has laid the foundation for everything we do:

Patients first.
Always.

Take care of each other.
Constantly.

Make no small plans.
Ever.

In 2021, we conducted our first environmental, social and governance (ESG) materiality assessment, supported by a global, third-party sustainability consultancy, to identify, prioritize and validate the ESG-related issues most significant to our business, our stakeholders and the broader context of the environment and society.

We undertook desktop research and conducted interviews with internal and external stakeholders to inform this assessment, resulting in the identification of the ESG issues material to our business.

As we reviewed the results, we found that our Ethos aligned organically with our ESG priorities, enabling us to integrate ESG into the core of who we are. As a result, we consolidated our material issues and directly linked them to our Ethos.

The **20 material topics** determined to be of greatest importance and impact to our internal and external stakeholders are:

Patients first. Always.

- Transformative Patient Experience
- Product Safety
- Access to Treatment
- Physician Awareness & Education
- Patient Data Privacy

Take care of each other. Constantly.

- Diversity & Inclusion
- Human Capital Management & Development
- Employee Wellbeing
- Occupational Health & Safety

No small plans. Ever.

- Product Design & Innovation
- Disease State Awareness & Guideline Development
- Supply Chain Management
- Product Lifecycle Management
- Intellectual Property

Our sustainable foundation

- ESG & Corporate Governance
- Ethics & Business Compliance
- Cybersecurity
- Operational Environmental Impacts
- Local Communities & Indirect Economic Impacts
- Climate and Geopolitical Resilience

Patients first. Always.

At Inari, patients are our passion. Every person has a story, a life and people who care, and we embrace the responsibility of our mission to treat and transform the lives of those suffering from complex diseases. Through innovative, purpose-built solutions, we work towards making the world just a little better, one patient at a time.

We think deeply about the responsibility of addressing unmet needs in VTE and other disease states. For appropriate opportunities, we organize our resources and expertise to develop purpose-built medical devices to help patients preserve their lives or live more fulfilling lives.

To learn more about our patients and their stories, please see the Patient Stories on our website.

Jessica, Age 44

Treated with **FlowTriever** system

Transformative Patient Experience

Transformation requires changing the healthcare system on behalf of patients. Most VTE patients are treated with anticoagulant drugs alone, despite ever increasing evidence supporting interventional therapy generally and mechanical thrombectomy specifically.

Alarmingly, many of these patients never see a physician who is a VTE expert.

75% of intermediate-high risk PE patients do not receive interventional consult[1]

We believe that the standard of care for the treatment of VTE will evolve to the use of anticoagulant drugs combined with catheter-based interventions, similar to that of other thrombotic diseases, such as heart attack and stroke.

1. Lacey MJ, et al. Prospective Experience of Pulmonary Embolism Management and Outcomes J Invasive Cardiol. 2021 Mar;33(3):E173-E180.

We believe our purpose-built products are further driving this evolution of treatment, and we are committed to changing the standard of care for DVT and PE.

In this regard, we hired a dedicated team of professionals to educate treating physicians and hospitals about the benefits of having a dedicated VTE response team, institutional guidelines for treatment of VTE and a comprehensive quality review of VTE programs.

VTE EXCELLENCE™

A Paradigm Shift in Venous Disease Patient Care

Our efforts to improve VTE treatment awareness and procedural excellence overlap with our continued push for more robust clinical evidence and collaboration with key stakeholders, including physicians that treat VTE and non-interventional stakeholders. We refer to our coordinated treatment approach as VTE Excellence.

An increasing number of hospitals have now installed VTE coordinators, who help ensure appropriate triage and treatment for patients, as a direct result of our VTE Excellence efforts.

We provide ongoing training and development for VTE coordinators throughout the United States. We continue to commit significant resources to VTE Excellence in order to ensure the best possible solutions and outcomes for our patients.

"The success of our VTE Excellence program has been driven by a robust, systematic process for identifying patients who can benefit from intervention."

—Michael Knox, MD, FACR
Interventional Radiologist
Advanced Radiology Services – Grand Rapids Spectrum Health Hospitals

We strive to create programs like the ones for heart attack and stroke ensure that patients who should receive interventional consultation for venous disease are not missed.



Product Safety

Product safety is at the core of everything we do for our patients. We control every aspect of the manufacturing process, manufacturing, assembling, inspecting, testing, packaging, and shipping our products from our 120,000 square foot facility in Irvine, California. As a medical device manufacturer, we manufacture our products in compliance with the FDA's Quality System Regulation, or QSR, and are subject to periodic inspections.

To supplement this, we have a supplier quality program that evaluates, qualifies, and approves suppliers to confirm conformance to relevant FDA and International Organization for Standardization (ISO) standards as well as our own specifications and requirements. We inspect and verify externally sourced product components under strict processes supported by our robust internal policies and procedures, and we maintain a rigorous change control policy to assure that no product or process changes are implemented without our prior review and approval.

To advance our goal of maintaining product quality and driving continuous improvement, we established a company-wide Quality Management System (QMS), certified to meet the ISO 13485:2016 standard. Our QMS includes processes for employee training, management review, internal quality audits and customer complaint tracking and reviews.

Our Quality Assurance (QA) team communicates our quality policy to all employees through meetings, training, and other means. Our QA team is a critical component of our research and development (R&D) efforts, and the team members collaborate with our engineering team to develop new products, source and test materials and monitor post-market performance with a focus on continuous improvement.

We launched **7** new products and had **0** product recalls in **2021**

Triever24
Catheters

FlowTriever2
Disks

FlowSaver
Blood Return System

Access to Treatment

Our devices currently treat approximately **5%** of the patients that could benefit from intervention.





We believe it is our responsibility to ensure access to treatment for all patients. This access starts with building clinical evidence. Since our inception, we have focused on generating clinical data to demonstrate the safety and efficacy of our products and build evidence to support updating the guidelines for the treatment of VTE.

The **PEERLESS** Trial

Peerless enrolls up to **700** Patients

Compares clinical trials at **60** Centers

Importantly, during 2021, we announced **PEERLESS**, our first randomized controlled trial. **PEERLESS** is a prospective, multi-center trial comparing the clinical outcomes of patients with intermediate-high risk PE treated with our **FlowTriever** device to those treated with catheter-directed thrombolysis.

We also have three registry studies underway - **CLOUT** for the **ClotTriever** system in DVT patients; **FLASH** for the **FlowTriever** system in PE patients; and **FLAME** specifically for high-risk PE patients. We are also pursuing many ongoing investigator-initiated studies.

Generating real world and broad evidence to drive adoption - including investment in RCTs

CLOUT

ClotTriever® System
Clinical Registry Study

Up to:
500 patients | **50** sites | **2** yr. f/u

Interim results in 250 pts. with a range of DVT clot chronicity:

- Excellent safety profile
- Significant clot removed
- Low rates of post-thrombotic syndrome

FLASH

FlowTriever® System
Percutaneous Pulmonary Embolectomy Clinical Registry Study

Up to:
1,000 patients | **100** sites | **6** mo. f/u

Interim results in 500 pts. with high & intermediate-risk PE:

- Excellent procedural safety
- Immediate on-table improvements
- Significant long-term mortality and QoL benefit

*Additional up to 300 patients in conservative arm sub study

FLAME

FlowTriever ® System
FLowTriever for Acute Massive Pulmonary Embolism

Up to:
71 patients | **20** sites | **In** hosp. f/u

Now enrolling: high-risk PE patients

Designed to impact practice guidelines

*Up to 71 patients in **FlowTriever** system front-line and up to 142 in context arm

PEERLESS

RCT of FlowTriever® vs. catheter-directed thrombolytics in pulmonary embolism

Up to:
550 patients | **60** sites | **30**-day f/u

Now enrolling: PE randomized controlled trial

RCT **FlowTriever** system vs. **catheter-directed thrombolysis** (CDT)

*550 patients in RCT + additional up to 150 pts. with contraindication to lytics in a registry arm

The largest prospective registries ever undertaken of a lytic-free, mechanical thrombectomy treatment for **DVT** and **PE.**

Physician Awareness & Education

We believe one of the biggest barriers to treatment of VTE and other complex diseases is lack of awareness.

As such, we dedicate significant resources to breaking down these barriers. We have an established and experienced team of medical education professionals who lead regular national, regional and local training and educational programs for both interventional and non-interventional physicians, nursing staff and other personnel involved in our procedures at hospitals.



Our medical affairs team,
led by our Chief Medical Officer, consists of four full-time physicians, including:

- two interventional cardiologists
- one interventional radiologist
- one pulmonologist with expertise in PE

ClotWarrior Academy

With our team of experts, we have greatly expanded our learning platform, the **Clot Warrior Academy,** to provide regular and interactive training to physicians. We host Advanced Users Forums to help physicians who are familiar with our devices and procedures learn additional and enhanced techniques. Because our sales representatives attend approximately 85% of procedures where our devices are used, we also have a robust sales training program to ensure they are able to support our treating physicians and keep them abreast of clinical and device-related updates.

Take care of each other. Constantly.

We believe that extraordinary outcomes are possible when a group of people commits together to ideas and purposes bigger than themselves and bigger than business. We invest in a team of people who commits themselves to our cause and to each other in pursuit of shared goals.

Alongside our focus on patients, we focus on our employees. Our approach is to select employees who align with Inari's mission and then retain and reward them as they build their careers.

Diversity & Inclusion

We are committed to creating and nurturing an inclusive workplace which is consistent with our Ethos. Everyone is respected, valued, and included–this is vital to our collaborative culture.

We are intentional in our efforts to build diverse teams that represent a variety of backgrounds, perspectives, and skills. We expect our employees at every level to speak up and share ideas.

At our home office, we have an open plan environment with no individual offices in order to foster collaboration and inclusivity across teams. Instead of walls, we have meeting spaces with glass walls, emphasizing the transparency that is key to our culture. We believe in hyper-communication from our senior management to all employees about the impact that ALL of our people have on our patients. We hold quarterly town halls where employees engage with our team, patients and physicians.



"We are breaking the glass ceiling but have so much more work to do to continue to advance equality for women and minorities. Representation matters and I'm proud to work for an organization that believes that."

Angela Grinstead Ahmad, *General Counsel*

Human Capital Management & Development

As of December 31, 2021, we had approximately 800 full-time employees. We employ a growing and highly skilled employee base across all functions and promote a culture focused on serving and improving the quality of life of our patients. We believe removing clots can have a profound impact on the lives of our patients over the short and long term, and it is our responsibility to ensure as many of our patients as possible are treated safely, effectively and simply. We have implemented hiring and recruiting systems to carefully select professionals who share these beliefs and goals. Our human capital objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and future employees. The principal purposes of our compensation plans are to attract, retain and motivate selected employees, consultants and directors. We do so through competitive salaries and cash-based performance awards, as well as through the granting of stock-based compensation awards.

Employee Wellbeing

Our employees are integral to delivering our mission, and we recognize our responsibility to take care of them. In addition to providing competitive salaries and offering a variety of benefit choices, we pay 100% of the health insurance premiums for employees and subsidize a significant portion of the premiums for their covered dependents. We also established the Inari Wellness program to encourage and reward our employees for making healthy lifestyle choices and we support our employees' ongoing professional and personal development with onsite training opportunities and an education assistance program.

Inari Wellness

Taking care of each other became even more relevant during the COVID-19 pandemic. During this time, we shut down our manufacturing facility on two separate occasions to protect our employees. Throughout the shutdowns, we paid our employees in full. In addition, we continue to pay for onsite and offsite COVID testing. Any absences due to COVID-19 symptoms or positive diagnosis were paid by the company without counting against an employee's paid time off balance. We continue to put our employees' health and safety at the forefront of everything we do.

For more information about our employees, please see our Careers Page and Life at Inari.

No small plans. Ever.

We are committed to changing the standard of care for treatment of venous and other diseases. With collaboration and input from key stakeholders, including physicians and non-interventional stakeholders, we aspire to change the status quo for our patients, our people, our medical community partners and our society.

We are committed to impacting our patients, physician partners and employees in a positive, life-changing manner. We do not focus on medical devices that may offer only marginal care or economic benefit to the patient or healthcare provider, but instead we develop solutions for complex disease states and significant unmet needs

Product Design & Innovation.

We have **over 65 engineers and technical staff** whose sole focus is enhancing our existing products and developing new, purpose-built solutions to treat unmet needs.

We believe our ability to develop innovative products is attributable to our focus on the specific anatomical system, our design philosophy and product innovation process, our efforts to leverage and expand our clinical evidence and the insights that we gained from developing our products to date. Our engineering team has broad mechanical and biomedical engineering, project management, materials science, design and prototyping expertise.

Our R&D efforts are informed by real-time, field-based input from our sales organization and physicians and the direct field experience of our engineers. We focus on developing the best treatment for patients and rely on feedback from our physician customers, who are at the front lines treating patients with VTE. This process has allowed us to rapidly innovate and enhance our products, and we continue to develop new products.

We are currently focused on **three key goals** as we develop additional and next generation products for commercialization.

- First, we seek to continue to enhance the effectiveness, efficiency and ease of use of our current products.
- Second, we plan to expand the application of our thrombectomy technology to areas of the body that are not addressed by our existing products.
- Third, we are developing solutions beyond our thrombectomy technology to address other unmet needs.

We spend more on R&D and clinical evidence building than our peers (as a percentage of revenue) and are looking to continue to grow these functions to ensure a better life for our current and future patients.



Our Sustainable Foundation

To uphold our Ethos, we rely on a strong foundation of thoughtful and sustainable practices that are core to our company, our company's growth trajectory and our long-term business resiliency. We commit to operating with integrity and in a manner that is protective of the environment and society.

ESG & Corporate Governance

Our Board of Directors presently comprises nine members, eight of which are considered independent from management. We consider diversity, such as gender, race and ethnicity, when identifying director nominees and view such diversity characteristics as meaningful to the composition of our Board. Currently, three of our nine directors are female, one of our directors identifies as LGBTQ+ and one of our directors identifies as Hispanic. Our Board has three standing committees: the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. At the committee level and as a whole, our Board has an active role in overseeing the management of company and our strategic goals.

In 2021, our Board gave the Nominating and Corporate Governance Committee oversight of Inari's sustainability principles, programs and practices, as well as reporting on these topics.

Following the materiality assessment, we formed a preliminary Ethos Council to lead the creation, implementation and communication of our ESG strategy, decision-making processes and disclosures. The council includes representatives from each of our key functions and operations, including those who are responsible for specific ESG topics or pillars described herein.

Where We Are Going

As we continue to grow, we are committed to sharing updates related to our programs, priorities, goals and performance. We will develop future reports with the aim of aligning our story and Ethos to the ESG information we believe is most useful to our stakeholders. In particular, during 2022 we plan to undertake ESG goal setting for our most material topics, focused on the following:

Patients first. Always.

- Launch multiple new products, both to enhance current product lines and to treat new, unmet needs
- Increase our focus on advocacy and awareness of VTE
- Continue the expansion of clinical evidence – for the benefit of all of our patients
- Pursue product enhancements and maintain our excellent product safety record

Take care of each other. Constantly.

- Expand benefits for our employees
- Maintain employee retention at levels well above our peer group
- Continue focusing on diversifying our employee base

No small plans. Ever.

- Enhance the training around our comprehensive compliance program
- Expand community impact and philanthropy
- Continue to invest significant amounts in R&D
- Continuous review of existing IP rights and IP strategy

Indications For Use: The FlowTriever system is indicated for (1) the non-surgical removal of emboli and thrombi from blood vessels (2) injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel. The FlowTriever system is intended for use in the peripheral vasculature and for the treatment of pulmonary embolism. Triever catheters are intended for use in peripheral vasculature and for the treatment of pulmonary embolism. The Triever catheters are also intended for use in treating clot in transit in the right atrium. The FlowTriever2 catheter is indicated for the non-surgical removal of emboli and thrombi from peripheral blood vessels. Injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The FlowTriever2 catheter is intended for use in the peripheral vasculature. The FlowSaver blood return system is used with Triever catheters for autologous blood transfusion. The Intri24 introducer sheath is indicated to provide a conduit for the insertion of endovascular devices into the vasculature while minimizing blood loss associated with such insertions. The ClotTriever thrombectomy system is indicated for: (1) the non-surgical removal of thrombi and emboli from blood vessels. (2) Injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The ClotTriever thrombectomy system is intended for use in the peripheral vasculature including deep vein thrombosis (DVT). The FlowStasis suture retention device is indicated for temporary suture retention following a percutaneous venous procedure.

See Instructions for Use for complete indications for use, contraindications, warnings, and precautions.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

INARI MEDICAL®

6001 Oak Canyon, Suite 100, Irvine, CA 92618 | InariMedical.com